Table 1 EC50 and Emax values of concentration-response curves performed for phenylephrine (PE), acetylcholine (ACh) and sodium nitroprusside (SNP) on 11–13 weeks female (F), 40–42 weeks female (F) and 40–42 weeks male (M) apoE-/- mice.
Dose of C60 fullerenes | EC50 (nM) | Emax (%) | ||||
|---|---|---|---|---|---|---|
11–13 weeks (F) | 40–42 weeks (F) | 40–42 weeks (M) | 11–13 weeks (F) | 40–42 weeks (F) | 40–42 weeks (M) | |
Vasoconstriction (PE) | ||||||
0.00 mg/kg | 9.0 (7.6–10.8) | 31.4 (23.6–41.7)¤ | 6.4 (5.5–7.3)¤ | 72.9 (70.4–75.4) | 65.6 (61.2–69.9)¤ | 71.3 (69.8–72.7) |
0.05 mg/kg | 8.7 (6.8–11.1) | 31.7 (25.2–39.8) | ND | 72.4 (69.1–75.6) | 71.1 (67.2–75.1) | ND |
0.50 mg/kg | 8.1 (6.6–10.0) | 38.9 (33.7–44.9) | 6.8 (5.3–8.7) | 73.7 (70.9–76.4) | 69.5 (67.0–72.0) | 67.0 (64.3–69.8)* |
Endothelium-dependent vasorelaxation (Ach) | ||||||
0.00 mg/kg | 44.3 (29.3–66.9) | 32.7 (17.6–66.6) | 161.6 (25.8–1022) | 70.8 (65.0–76.5) | 60.4 (53.2–67.6) | 26.7 (13.0–40.4)¤ |
0.05 mg/kg | 44.7 (27.4–72.8) | 10.5 (4.7–23.4) | ND | 58.7 (52.9–64.4)* | 37.8 (32.6–43.0)* | ND |
0.50 mg/kg | 52.6 (38.6–71.8) | 19.7 (6.9–56.1) | 148.4 (7.7–2847) | 60.0 (55.9–64.2)* | 47.3 (38.6–56.0) | 34.4 (4.9–41.9) |
Endothelium-independent vasorelaxation (SNP) | ||||||
0.00 mg/kg | 10.1 (8.1–12.6) | 19.9 (14.4–27.4)¤ | 22.9 (15.8–33.1)¤ | 93.2 (90.1–96.3) | 82.3 (77.8–86.8)¤ | 70.3 (65.4–75.2)¤ |
0.05 mg/kg | 15.7 (11.2–22.0) | 13.6 (8.2–22.5) | ND | 86.6 (81.9–91.2) | 80.2 (73.7–86.7) | ND |
0.50 mg/kg | 16.5 (13.4–20.3)* | 20.9 (16.3–26.8) | 20.3 (10.6–39.2) | 88.3 (85.1–91.6) | 83.3 (79.6–87.0) | 58.5 (52.2–66.8) |